CD20/BCMA-directed CAR-T cells Clinical Trials

1 actively recruiting trial

Also known as: C-CAR168

Pipeline

Phase 1: 1

Top Sponsors

RenJi Hospital1

Indications

Systemic Sclerosis (SSc)1
Multiple Sclerosis (MS)1
Neuromyelitis Optica Spectrum Disorders (NMOSD)1
Immune-mediated Necrotizing Myopathy (IMNM)1
Systemic Lupus Erythematosus (SLE)1

Other1 trial

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.